Surveillance of extensively drug-resistant tuberculosis in Europe, 2003-2007

Eurosurveillance

Volumn 15, Issue 11, 2010, Pages 15-20

  Devaux, I ^a,b   Manissero, D ^b   Fernandez de la Hoz, K ^b,c   Kremer, K ^d   van Soolingen, D ^d  

^a INSTITUT DE VEILLE SANITAIRE   (France)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c National Institute for Public Health and the Environment ^*

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; KANAMYCIN; OFLOXACIN;

ARTICLE; DISEASE SURVEILLANCE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 77952539224     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanca RB, Herrera C, et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One. 2008;3(8):e2957.
2. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E, Raviglion M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther. 2007;5(5):857-71.
3. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J. 2007;30(4):623-6.
4. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006;55:301-5.
5. Goldman C, Kevin V, Plumley, Laughon BE. The evolution of extensively drug resistant tuberculosis (XDR TB): History, status and issues for global control. Infectious Disorders - Drug Targets. Volume 7, Number 2, June 2007, p. 73-91(19).
6. Guerrero A, Cobo J, Fortún J. Navas E, Quereda C, Asensio A, et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet. 1997;350(9093):1738-42.
7. Alexander PE, De P. The emergence of extensively drug- resistant tuberculosis (TB): TB/HIV coinfection, multidrug- resistant TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada. Can J Infect Dis Med Microbiol. 2007;18(5):289-91.
8. Manissero D, Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR TB) and relevance to Europe: summary update. Euro Surveill. 2006;11(44). pii=3070. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3070
9. Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis--United States, 1993-2006. MMWR Morb Mortal Wkly Rep. 2007;56(11):250-3.
10. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368(9553):2142-54.
11. World Health Organization/International Union Against TB and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-Tuberculosis Drug Resistance in the World: Fourth Global Report. 2008. Available from: http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf
12. Manissero D, Fernandez de la Hoz K. Extensive drug-resistant TB: a threat for Europe? Euro Surveill. 2006;11(39). pii=3056. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3056
13. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575-80.
14. Devaux I, Kremer K, Heersma H, Van Soolingen D. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerg Infect Dis. 2009;15(7):1052-60.
15. World Health Organization/International Union Against TB and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Report no. 3. 2008 Available from: http://www.who.int/tb/publications/who_htm_tb_2004_343/en/
16. EuroTB. European surveillance of multidrug resistant tuberculosis EuroTB/RIVM. Main Data File Specification for reporting MDR-TB cases. Summary version October 2005. Available from: http://www.eurotb.org/mdr_tb_surveillance/pdf/dfs_nsi_short.pdf
17. EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 2006, Institut de veille sanitaire, Saint-Maurice, France. March 2008. Available from: http://www.eurotb.org/rapports/2006/full_report.pdf
18. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug- resistant tuberculosis. Emerg Infect Dis. 2007;13(3):380-7.
19. Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, Loddenkemper R, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J. 2002 Apr;19(4):765-75.
20. Mor Z, Migliori GB, Althomsons SP, Loddenkemper R, Trnka L, Iademarco MF. Comparison of tuberculosis surveillance systems in low-incidence industrialised countries. Eur Respir J. 2008;32(6):1616-24.
21. World Health Organization (WHO). Policy guidance on drug- susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. Geneva 2008. Available from: http://www.who.int/tb/features_archive/xdr_mdr_policy_guidance/en/index.html
22. Rüsch-Gerdes, S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44(3):688-92.
23. van Ingen J, Boeree MJ, Wright A, van der Laan T, Dekhuijzen PNR, van Soolingen D. Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands. Int. J. Tuberc Lung Dis. 2008;12(11):1295-9.
24. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009;323(5918):1215-8.
25. Drobniewski F, Rüsch-Gerdes S, Hoffner S, Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1) -- report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect. 2007;13 (12):1144-56.
26. Drobniewski FA, Nikolayevskyy V, Hoffner S, Pogoryelova O, Manissero D, Ozin AJ. The added value of a European Union tuberculosis reference laboratory network - analysis of the national reference laboratory activities. Euro Surveill. 2008;13(12). pii=8076. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8076